Kyle Mikson: Okay. That was great. And then maybe just thinking about GeoMx specifically just staying on that, going forward, I guess, spatial order is one-third being GeoMx sounded like that was the expectation? Maybe just talk about your confidence in the health of that franchise and kind of the visibility heading into 2023 and beyond. And I was also curious if NGS readout and WTA as much as €“ because how much of a headwind €“ a tailwind that I thought that might have been last year or the year earlier? Thanks.
Brad Gray : Yes. I’ll take the second question first again Kyle. WTA and NGS readout now represent the vast majority of the GeoMx system. 85% of our new systems are placed in front of the sequencers and the whole transcriptome Atlas assays account for something like 75% of our consumable revenue. So, that’s been really a successful story. We’re also long-term optimistic about the value of the GeoMx franchise. The science speaks for itself. It’s no small thing to be on the cover of two different journals within just a few months’ time. We now have a 160 peer-reviewed papers, 30 a quarter getting published. This for translational researchers who are doing immunology oncology, this is a very productive and powerful instrument. I do think the idea of single cell imaging is sucking a lot of the oxygen out of the room right now with respect to people who are building their new spatial capabilities, but in the long-term, we still believe GeoMx has an important place.
And I think the best evidence we have today for that is the strong synergy between CosMx and GeoMx when it comes to who’s purchasing the CosMx systems, a very large fraction of those who are buying CosMx are either doing so with a GeoMx in a bundle or labs who already purchased a GeoMx. and want to have complementary capabilities.
Kyle Mikson: All right. Perfect. And then just one more before I hop-off, just on the 2023 outlook, I guess. And I know you’re not going to provide much detail until it will be on the 4Q call, but Tom or Brad, a lot of those hinges upon GeoMx next year including pull-through, I mean, how should we sort of think about that as we kind of model going ahead here? Thanks.
Tom Bailey: Yes, I think the first answer is obviously we’ll provide more detail that we already filed with. Setting that aside what we built our growth rate ranges, we didn’t make heroic assumptions around GeoMx. I think that you can get to our numbers by assuming GeoMx repeats what it does €“ what it did this year for instruments and that pull-through competes what it did this year as well. And you can get to those growth rate ranges with those conservative assumptions. So, we’ll comment more in February.
Kyle Mikson: Okay, got it. And just to repeat, the range was 40% to 50% growth and I think it was a backlog for CosMx of , is that correct?
Tom Bailey : $23 million currently and we expect that to be about $30 million by the end of the year, in dollar terms.
Kyle Mikson: Perfect. Okay. All right, guys. I’ll leave it there. Thanks so much for the questions. Appreciate it.
Brad Gray: Thank you, Kyle.
Operator: Thank you. Our next question comes from the line of Dan Brennan with Cowen. Your line is now open.
